Abstract:Introduction: HCC is an aggressive and genetic heterogeneous disease. Several disrupted signaling pathways have been identified, though actionable targets are limited. The majority of systemic chemotherapy and targeted therapy (tyrosine kinase inhibitors (TKIs) or monoclonal antibodies) have demonstrated minimal to no clinical activity. Immunotherapy has emerged as a potentially transformative strategy with attractive and long-lasting responses in HCC. However, the clinical efficacy of immune check point blockades (ICB) is limited to a select subset of patients and is hampered by drug resistance. Methods: In this study, we focused on tumor cell intrinsic factors and conducted a hybridization-capture methodology and targeted 1 Mb of genomic coding sequence ( Gene Plus1021 Panel). Analysis of 81 HCC tumors and matching plasma normal samples was performed to characterize the landscape of somatic mutations especially those related to the sensitivity, resistance and hyper progression of ICB therapy in HCC. For genes identified in our study significantly correlated with tumor mutational burden (TMB), We further did the verification in The Cancer Genome Atlas (TCGA)-LIHC. 363 HCC tumor samples were included in the cohort and the data was downloaded from cBioPortal website (http://www.cbioportal.org/). Results: We analyzed 81 HCC tumor samples accepted in Peking University International Hospital from January 2015 to Jun 2018 who did not receive ICB therapy at the time of taking specimen. The top quartile (7 muts/Mb) of TMB distribution was used as the cutoff value to define high tumor mutational burden (TMB-H). There were 26 cases (32.10%) with high TMB. Among all the 81 samples analyzed we detected no mismatch repair deficiency (dMMR), but identified five gene mutations having a significant correlation with high TMB including TP53, CTNNB1, ARID1A, MLL and NCOR1, p=0.0439, 0.0196, 0.0023, 0.0247 and 0.0076, retrospectively. We further did the verification in The Cancer Genome Atlas (TCGA)-LIHC. Gene mutations of TP53, CTNNB1, and MLL were proved to be highly associated with TMB-H status, p=0.0009, 0.0016 and 0.0013, retrospectively. Moreover, gene mutations of ARID1A, TP53 and MLL were proved to implicate poor overall survival. We detected 2 mutations (2.47%) in POLE, 2 mutations (2.47%) in PTEN, 1 mutation (1.23%) in DNMT3A, and 1 sample (1.23%) with high microsatellite instability (MSI-H). TMB value for the only one sample in MSI-H status was 9 muts/Mb (TMB-H). Instead of dMMR, one TP53 mutation and one ARID1A mutation were detected in this sample. Conclusions: TMB-high and crucial driver gene mutations associated with high mutation load should be evaluated as potential predictive biomarkers in datasets of HCC patients treated with ICB therapy. Note: This abstract was not presented at the meeting. Citation Format: Li Li, Zhaohong Wen, Michael J. Overman, Xiaosong Rao, Yuting Yi, Yanfang Guan, Jun Liang. Identification of mutational landscape predicting efficacy of immune checkpoint blockades and recurrent mutations related to high tumor mutational burden in hepatocellular carcinoma by next generation sequencing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1255.

The Predictive Values of Loss-of-function Variants in Histone Methyltransferases for Response to Immune Checkpoint Inhibitors in Solid Tumors.

Association of KMT2C/D Loss-of-function Variants with Response to Immune Checkpoint Blockades in Colorectal Cancer

KMT2C As a Positive Predictor for Treatment of Immune Checkpoint Inhibitor and Correlation with Immune Infiltrates in Colorectal Cancer (CRC).

KMT2A/C Mutations Function As a Potential Predictive Biomarker for Immunotherapy in Solid Tumors

Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments

A Pan-Cancer Study of KMT2 Family As Therapeutic Targets in Cancer

Pan‐cancer analysis on the role of KMT2C expression in tumor progression and immunotherapy

Associations Between Interaction Effects of Mutational Events and Efficient Immunotherapy in Squamous NSCLC: Results from 373 Patients.

Comprehensive analysis of TMB, TNB, and HLA via NGS sequencing in a large cohort of Chinese pan-cancer patients.

Association of KMT2C loss-of-function mutations in circulating tumor DNA and prolonged response to the combination of PARPi and PI3Ki.

Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer

Large-Scale Cancer Genomic Analysis Reveals Significant Disparities Between Microsatellite Instability and Tumor Mutational Burden

Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer

Analysis of the Role of Mutations in the KMT2D Histone Lysine Methyltransferase in Bladder Cancer

Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced non-small cell lung cancer.

Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types

Mutational landscape of homologous recombination-related genes in small-cell lung cancer

Abstract 1255: Identification of Mutational Landscape Predicting Efficacy of Immune Checkpoint Blockades and Recurrent Mutations Related to High Tumor Mutational Burden in Hepatocellular Carcinoma by Next Generation Sequencing

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent manner

Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma